The Transformative Role of AI in Pharma – An Exploration
What is Artificial Intelligence? Artificial Intelligence (AI) is a field of computer science that aims to mimic human intelligence, enabling machines to learn from experience, adjust to new inputs, and perform tasks that normally require human intelligence. It’s a broad term encompassing various technologies, including machine learning, natural language processing, and vision technologies. AI’s impact […]
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In the article titled “Kurt Herpel: Revolutionizing Drug Discovery Through Artificial Intelligence,” Kurt shares his vision for the future of drug discovery, highlighting the transformative potential of artificial intelligence (AI) in advancing healthcare solutions. AI and […]
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Prof. Doron Lancet will join its Scientific Advisory Board. Prof. Lancet is a distinguished scientist in the area of genetics and systems biology. “We are excited to have Prof. […]
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often progress to end-stage renal disease requiring dialysis and/or kidney transplantation, adding a significant socioeconomic burden to the individual burden of patients. There are approximately 140.000 patients with FSGS worldwide, qualifying […]
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology industry. What is Bio-Europe? The Bio-Europe conference is an annual event that serves as the largest partnering conference in the life sciences sector, focusing on the biotechnology and pharmaceutical industries. The conference, organized by EBD […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Dr. Hans Lehrach will join its Scientific Advisory Board. Prof. Lehrach is a distinguished scientist in the area of genomics. „We are excited to have Dr. Lehrach join our […]
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings to Delta4 a deep financial expertise from his 20 years with banks in Austria and Switzerland, and as a CFO and Business Angel Investor working with start-ups and young businesses. We are looking forward to […]
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified in Current Discovery Programs Ready for Clinical Development Vienna, Europe (April 7, 2021) – Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that it […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed four patent applications for compounds and combinations of compounds for the treatment of FSGS, a rare kidney disease with only limited therapeutic options, and COVID-19. Today, drug candidates from both programs have been biologically validated […]